Third Harmonic Bio logo — Advancing the next wave of medicine for inflammatory disease...

Third Harmonic Bio

Advancing the next wave of medicine for inflammatory diseases

Founded 2019 United States San Francisco, United States 8 employees Series B Total: $155.00M Biotechnology, Health Care +1

General Information

Company Name Third Harmonic Bio
Founded Year 2019
Location United States San Francisco, United States
Employees 8
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Third Harmonic Bio. To contact Third Harmonic Bio, visit thirdharmonicbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Third Harmonic Bio compare?

A PDF of Third Harmonic Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Third Harmonic Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Third Harmonic Bio

Third Harmonic Bio, founded in 2019, is a clinical-stage biopharmaceutical company with the slogan "Advancing the next wave of medicine for inflammatory diseases." The company is focused on developing a highly selective, oral KIT inhibitor for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. Their approach revolves around targeting KIT, a cell surface receptor that plays a crucial role in regulating mast cells, the key mediators of inflammation in mast-cell mediated inflammatory diseases. By inhibiting KIT, Third Harmonic Bio aims to provide broad symptomatic relief for patients with conditions such as chronic spontaneous urticaria and severe asthma. In January 2022, the company successfully secured a $105.00M Series B investment from a consortium of prominent investors including General Atlantic, RA Capital Management, Boxer Capital, Ajax Health, Commodore Capital, Deep Track Capital, RTW Investments, and Biotechnology Value Fund. With a focus on biotechnology and healthcare industries, Third Harmonic Bio stands at the forefront of innovative solutions for inflammatory diseases.

Business keywords: biopharmaceutical, clinical-stage, KIT inhibitor, inflammatory diseases, dermal diseases, respiratory diseases, gastrointestinal diseases, mast cells, chronic spontaneous urticaria, severe asthma, allergy, allergic diseases, immune cells, drug development, medical research

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $105.00M 8
General Atlantic, RA Capital Management +6
16 Jan 2022
Series A $50.00M 2
OrbiMed, Biotechnology Value Fund
01 Jan 2019

Third Harmonic Bio Alternatives & Competitors

View All Alternatives
Third Harmonic Bio vs

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care
Third Harmonic Bio vs
Upstream Bio
Upstream Bio United States

Developing treatments for inflammatory diseases

IPO
78 employees
Biotechnology, Health Care
Third Harmonic Bio vs
Allakos Inc
Allakos Inc United States

Antibody-based therapeutics to treat various allergies and diseases

Acquired
24 employees
Biopharma, Biotechnology

FAQ About Third Harmonic Bio

Advancing the next wave of medicine for inflammatory diseases
Third Harmonic Bio was founded in 2019.
Third Harmonic Bio is headquartered in San Francisco, United States.
Third Harmonic Bio operates in Biotechnology, Health Care and Life Sciences. Its work centres on biopharmaceutical, clinical-stage, KIT inhibitor and inflammatory diseases.
Third Harmonic Bio has approximately 8 employees.
Third Harmonic Bio has completed 2 funding rounds, raising a total of $155.00M. The latest funding stage is Series B.
Top alternatives and competitors to Third Harmonic Bio include Entero Therapeutics (Nasdaq: ENTO), Upstream Bio, Allakos Inc, EpiEndo Pharmaceuticals, Synta Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Third Harmonic Bio and Entero Therapeutics (Nasdaq: ENTO) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Third Harmonic Bio, https://bouncewatch.com/company/third-harmonic-bio, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes